Clinical pharmacokinetics of statins

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 25, Issue 6, 2003, Pages 457-481

  Garcia M J ^b   Reinoso, R F ^a   Sanchez Navarro A ^b   Prous, J R ^a  

^a PROUS SCIENCE   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Clinical studies; HMG CoA; Pharmacokinetics; Reductase inhibitors; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; GLENVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; FIRST PASS EFFECT; HYPERCHOLESTEROLEMIA; INTESTINE; LIVER; METABOLITE; PROTEIN BINDING; REVIEW; URINARY EXCRETION;

EID: 0141569210     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2003.25.6.769652     Document Type: Review

References (105)

1. Reinoso, R.F., Sánchez Navarro, A., García, M.J., Prous, J.R. Pharmacokinetic interactions of statins. Methods Find Exp Clin Pharmacol 2001, 23(10): 541-66.
2. Reinoso, R.F., Sánchez Navarro, A., García, M.J., Prous, J.R. Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2002, 24(9): 593-613.
3. Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., Bernini, F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999, 84: 413-28.
4. Malinowski, J.M. Atorvastatins: A hydroxymethylglutaryl-coenzime A reductase inhibitor. Am J Health-Syst Pharm 1998; 55: 2253-67.
5. Cilla, D.D., Whitfield, L.L.R., Gibson, D.M., Sedman, A.J., Posvar, E.L. Multiple-dose pharmacokinetics, pharmacodyuamics and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996, 60: 687-95.
6. Stern, R.H., Bing-Bing, Y., Hounslow, N.J., MacMahon, M., Abel, R.B., Olson, S. Pharmacodynamics and pharmcokinetic-pharmcodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 2000, 40: 616-23.
7. Cilla, D.D., Gibson, D.M., Whitfield, L.L.R., Sedman, A. Pharmacodynamic effect and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996, 36: 604-9.
8. Shum, Y.Y., Huang, H., Walter, G. et al. Development and validation of an enzymatic inhibition assay for quantitation of CI-981 in human plasma [Abstract]. Pharm Res 10 (Suppl): S415.
9. Yang, B.B., Smithers, J.A., Stern, H.R., Sedman, A.J., Olson, S.C. Pharmacokinetics and dose-proportionality of atorvastatin and its active metabolites [Abstract]. Pharm Res 1996; 9 (Suppl): S437.
10. Oishi, S., Watanabe, T., Higuchi S. et al. Atorvastatin (CI-981). Clinical pharmacokinetic study (I) - relative bioavailability of amorphous and crystalline preparations of atorvastatin. Jpn Pharmacol Ther 1998, 26: 67-78.
11. Oishi, S., Watanabe, T., Higuchi S. et al. Atorvastatin (CI-981). Clinical pharmacokinetic study (II) - pharmacokinetics of single dose atorvastatin in healthy male volunteers. Jpn Pharmacol Ther 1998, 26: 79-92.
12. Posvar, E., Radulovic, L.L., Cilla, D.D., Whitfield, L.L.R., Sedman, A. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol 1996, 36: 728-31.
13. Wu, X., Lloyd, R., Whitfield, L.L.R., Stewart, B.H. Atorvastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid Co-transporter. Pharm Res 2000, 17: 209-15.
14. Lea, A.P., McTavish, D. Atorvastatin. A review of its pharmacology and therapeutical potential in the management of hyperlipidaemias. Drugs 1997, 53: 828-47.
15. Jacobsen, W., Kuhn, B., Soldner, A. et al. Lactonization is the critical first step in the disposition of the ofthe 3-hydroxy-3 methylglutaryl-CoA reductase inhibitor atrovastatin. Drug Metab Dispos 2000, 28: 1369-78.
16. Gibson, D.M., Bron, N.J., Richens, A., Hounslow, N.J., Sedman, A.J., Whitfield, L.L.R. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1999, 36: 242-6.
17. Christians, U., Jacobsen, W., Floren, L.C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are statins mechanistically similar? Pharmacol Ther 1998, 80: 1-34.
18. Whitfield, L.R., Cilla, D.D., Posvar, E.L., Sedman, A.J., Gibson, D.M. Single- and multiple-dose pharmacokinetics of CI-981, a potent HMG-CoA reductase inhibitor [Abstract]. Pharm Res 1993, 10 (Suppl): PPDM 8167.
19. Oishi, S., Watanabe, T., Higuchi S. et al. Atorvastatin (CI-981). Clinical pharmacokinetic study (IV) - pharmacokinetics of multiple dose atorvastatin in healthy male volunteers. Jpn Pharmacol Ther 1998, 26: 105-19.
20. Oishi, S., Watanabe, T., Higuchi S. et al. Atorvastatin (CI-981). Clinical pharmacokinetic study (V) - pharmacokinetics of single dose atorvastatin in healthy young and elderly volunteers. Jpn Pharmacol Ther 1998, 26: 121-31.
21. Gibson, D.M., Yang, B-B., Abel, R.B et al. Effects of hepatic and renal impairment on pharmacokinetics (PK) and pharmacodynamics (PD) of atorvastatin [Abstract]. Pharm Res 1996; 13 (Suppl 9): S428.
22. Stern, R.H., Yang, B-B., Horton, M., Moore, S., Abel, R.B., Olson, S.C. Renal dysfunction does not alter the pharmacokinetics of LDL-Cholesterol reduction of atorvastatin. J Clin Pharmacol 1997, 37: 816-19.
23. Jemal, M., Rao, S., Salahudeen, I. et al. Quantitation of cerivastatin and its seven acid and lactone biotransformation products in human serum by liquid-electrospray tandem mass spectrometry. J Chromatography B 1999, 736: 19-41.
24. Mück, W., Ritter, W., Ochmamm, K. et al. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivasatin. Int J Clin Pharmacol Ther 1997, 35: 255-60.
25. Boberg, M., Angerbauer, R., Kanhai, W. et al. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolite pathways and an of cytochrome P450 isozymes involved. Drug Metab Disp 1997, 25: 321-31.
26. Stein, E., Isaacsohn, J., Stoltz, R. et al. Pharmacodynamics, safety, tolerability and pharmacokinetics of the 0.8 mg dose of cerivastatin in patients with primary hypercholesterolemia. Am J Cardiol 1999, 83(5): 1433-6.
27. Mück, W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokin 2000, 39: 102-16.
28. Bischoff, H., Heller, A.H. Preclinical and clinical pharmacology of cerivastatin. Am J Cardiology 1998, 27: 18J-25J.
29. Múck, W., Frey, R., Unger, S., Voith, B. Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening. Int J Clin Pharm Ther 2000, 38: 298-303.
30. Bischoff, H., Angerbauer, R., Boberg, M. et al. Preclinical review of cedvastatin sodium: A step forward in HMG-CoA reductase inhibition. Atherosclerosis 1998; 139 Suppl: S7-13.
31. Boberg, M., Angerbauer, R., Kanhai, W. et al. (C)BAY w 6228: Biotransformation in human liver microsomes in vitro. Characterization of primary metabolite pathways and of cytochrome P450 isoenzymes involved. Drug Metab Dispos 1997; 25: 321-31.
32. Múck, W., Unger S., Kavano, K., Ahr G. Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. British J Clin Pharmacol 1998, 45: 583-90.
33. Mazzu, A.L., Lettieri, J.T., Kelly, E. et al. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults. Eur J Clin Pharmacol 2000; 56: 69-74.
34. Isaacsohn, J., Zinny, M., Mazzu, A., Lettieri, J., Heller, A.H. Influence of gender on the pharmacokinetics, safety and tolerability of cerivastatin in healthy adults. Eur J Clin Pharmacol 2001, 56: 897-903.
35. Mück, W., Park, S., Jager, W. et al. The pharmacokinetics of cerivastatin in patients on chronic hemodialysis. Int J Clin Pharmacol Ther 2001, 39: 192-8.
36. Scripture, C.D., Pieper, J.A. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001, 40: 263-81.
37. Tse, F.L.S., Jaffe, J.M., Troendle, A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992, 32: 630-8.
38. Delyspere, J.P. Clinical implications of the biopharmaceutical properties of fluvastatin. Am J Cardiol 1994, 73: 12D-17D.
39. Lindahl, A., Sandström, R., Ungell, A.L. et al. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin Pharmacol Ther 1996, 60: 493-503.
40. Sabia, H., Prasad, P., Smith, H.T., Stolz, R.R., Rothenberg, P. Safety, tolerability and pharmacokinetics of an extended-release formulation of fluvastatin administered once-daily to patients with primary hypercholesterolemia. J Cardiovascular Pharmacol 2001, 37: 502-11.
41. Tse, F.L.S., Nikerson, D.F., Yardley, W.S. Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci 1993, 82: 942-7.
42. Dain, J.G., Fu, E., Gorski, J., Nicoletti, J., Scallen, T.J. Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 1993, 21: 567-72.
43. Fischer, V., Johanson, L., Heitz, F. et al. The 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999, 27: 410-16.
44. Appel, S., Dingemanse, J. Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors. Drugs Today 1996, 32 (Suppl A): 37-55.
45. Nakaya N., Maeda, A., Irie, N. et al. Phase I studies of HR780, an inhibitor of HMG-CoA reductase [Abstract]. Atherosclerosis 1994, 109: 254.
46. Tang, B.K., Kalow, J.P. Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. Eur J Clin Pharmacol 1995, 47: 449-51.
47. Duggan, D.E., Chen, I.W., Bayne, W.F. et al. The physiological disposition of lovastatin. Drug Metab Dispos 1989, 17: 166-73.
48. Frishman, W.H., Zimetbaum, P., Nadelmann, J. Lovastatin and other HMG-CoA reductase inhibitors. J Clin Pharmacol 1988, 29: 975-82.
49. Desager, J.P., Horsmans, Y. Clinical pharmacokinetics of 3hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996, 31: 348-71.
50. Pan, H.Y., DeVault, A.R., Wang-Iverson, D., Ivashkiv, E., Swanson, B.N., Sugerman, A.A. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990, 30: 1128-35.
51. Henwood, J.M., Heel, R.C. Lovastatin, a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidemia. Drugs 1988, 36: 429-54.
52. Pentikainen, P.J., Saraheimo, M., Schwartz, J.I. et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992, 32: 136-40.
53. Jacobsen, W., Kirchner, G., Hallensleben, K. et al. Small intestine metabolism of the 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther 1999, 291: 131-9.
54. Benct, L.Z., Wu, C.Y., Hebert, M.F., Wacher, V.J. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J Controlled Release 1996, 39: 139-43.
55. Holmberg, M., Sandberg, C., Nygren, P. et al. Effects of lovastatin on a human myeloma cell line:increased sensitivity of a multidrug resistant subline that expresses the 170 dDa P-glycoprotein. Anticancer Drugs 1994, 5: 598-600.
56. Hunter, J., Hirst, B.H. Intestinal secretion of drugs. The role of P-glycoprotein and related drug afflux systems in limiting oral absorption. Adv Drug Delivery Rev 1997, 25: 129-57.
57. Lennernäs, H., Fager, G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997, 32: 403-25,
58. Lown, K.S., Mayo, R.R., Leichtnan, A.B. et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997, 62: 248-60.
59. Duggan, D.E., Vickers, S. Physiological disposition of HMG-CoA reductase inhibitors. Drug Metab Rev 1990, 22: 333-62.
60. Cheng, H., Sutton, S.C., Pipkin, J.D. et al. Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methyl-glutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans. Pharm Res 1993, 10: 1683-7.
61. Botti, R.E., Triscari, J., Pan, H.Y., Zayat, J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991, 14: 256-61.
62. Garnett, W.R. Interactions with hydroxyntethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm 1995, 52: 1639-45.
63. Halpin, R.A., Ulm, E.H., Till, A.E. et al. Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos 1993, 21: 1003-1111.
64. Wang, R.W., Kari, P.H., Lu, A.Y., Thomas, P.E., Guengerich, F.P., Vyas, K.P. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991, 290: 355-61.
65. Jacobsen, W., Kirchner, G., Hallensleben, K. et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutalyl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999, 27: 173-9.
66. Quérin, S., Lambert, R., Cusson, J.R. et al. Single-dose pharmacokinetics of 14C-lovastatin in chronic renal failure. Clin Pharmacol Ther 1991, 50: 437-41.
67. Pan, H.Y., Triscari, J., DeVault, A.R. et al. Pharmacokinetic interaction between propranolol and HMG-CoA reductase inhibition pravastain and lovastatin. Br J Clin Pharmacol 1991, 31: 665-70.
68. Cheng, H., Rogers, J.D., Sweany, A.E. et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitory activity of lowing multiple dosing of lovastatin and simvastatin. Pharm Res 1992, 9: 1629-33.
69. Kajinami, K., Mabuchi, H., Saito, Y. NK-104: A novel synthetic HMG-CoA reductase inhibitor. Exp Opin Invest Drugs 2000, 9: 2653-61.
70. Fujino, H., Yamada, I., Kojima, J., Hirano, M., Matsumoto, H., Yoneda, M. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA redactase: In vitro metabolism and plasma protein binding in animals and human. Xenobio Metab Dispos 1999, 14: 415-24.
71. Fujino, H., Kojima, J., Yamada, Y., Kanda, H., Kimata, H. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): Interspecies variation in laboratory, animals and humans. Xenobio Metab Dispos 1999, 14: 79-91.
72. Serajuddin, A.T.M., Ranadive, S.A., Mahoney, E.M. Relative lipophilicities, solubilities and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin and simvastatin. J Pharm Sci 1991, 80: 830-34.
73. Jungnickel, P.W., Cantral, K.A., Maloley, A. Pravastatin: A new drag for the treatment of hypercholesterolemia. Clin Pharm 1992, 11: 677-89.
74. Hatanaka, T. Clinical pharmacokinetics of pravastatin. Mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000, 39: 397-412.
75. Triscari, J., O'Donnell, D., Zinny, M., Pan, H.Y. Gastrointestinal absorption of pravastatin in healthy volunteers. J Clin Pharmacol 1995, 35:142-4.
76. Ito, M.K. Effects of extensive and poor gastrointestinal metabolism on the pharmacodynamics of pravastatin. J Clin Pharmacol 1998, 38: 331-6.
77. Palmisano, M., Hammett, J., Jemal, M., Norton, J., Ford, N. An oral single rising high dose tolerance study of pravastatin in healthy subjects [Abstract]. 13th Int Symp Drugs Affect Lipid Metab (May 30-June 3, 1998, Florence) 1998, pp 68.
78. Sigurbjörnsson, S., Kjartansdóttir, T., Jóhannsson M., Kristinsson, J., Sigurdsson, G. A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers. Eur J Drug Metab Pharmacokin 1998, 23: 13-18.
79. Pan, H.Y., DeVault, A.R., Swites, B.J. et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestiramine in hypercholesterolemia. Clin Pharmacol Ther 1990, 48: 201-7.
80. Singhvi, S.M., Pan, H.Y., Morrison, R.A., Willard, D.A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990, 29: 239-43.
81. Hsu, I., Spinler, S.A., Johnson, N.F. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitors in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995, 26: 743-58.
82. Wang, E., Casciano, C.N., Clement, R.P., Johnson, W.W. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors ofP-glycoprotein. Pharm Res 2001, 18: 800-6.
83. Pan, H., Fleiss, P., Moore, L. et al. Excretion of pravastatin, an HMG CoA reductase inhibitor, in breast milk of lactating women (Abstr). J Clin Pharmacol 1988, 28; 942.
84. Everett, D.W., Chando, T.J., Didonato, G.C., Singhvi, S.M., Pan, H.Y., Weinstein, S.H. Biotransformation of pravastatin sodium in hnmans. Drug Metab Dispos 1991, 19: 740-8.
85. Pan, H.Y., DeVault, A.R., Brescia, D. et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993, 31: 291-4.
86. Pan, H.Y., Waclawski, A.P., Funke, P.T., Whigan, D. Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 1993, 27: 1029-33.
87. Gehr, T.W.B., Sica, D.A., Slugg, P.H., Hammett, J.L., Raymond, R., Ford, N.F. The pharmacokinetics of pravastatin in patients on chronic hemodialysis. Eur J Clin Pharmacol 1997, 53: 117-21.
88. Halstenson, C.E., Triscari, J., DeVault, A., Shapiro, B., Keane, W., Pan, H. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 1992, 32:124-32.
89. McTaggart, F.M., Buckett, L., Davidson, R. et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methyl-glutaryl coenzyme A redactase inhibitor. Am J Cardiol 2001, 87: 28B-32B.
90. Hanefeld, M. Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor. Int J Clin Pharmacol 2001, 55: 399-405.
91. Martín, P.D., Dane, A.L., Schneck, D.W., Warwick, M.J. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy sabjects. [Abstract]. J Clin Pharmacol 2000, 40: 1056.
92. Martin, P.D., Mitcheli, P.D., Schneck, D.W. Pharmacodynamic effects and pharmacokinetics of new HMG-CoA reductase inhibitor ZD4522 after am and pm administration in healthy subjects. [Abstract]. J Clin Pharmacol 2000, 40: 1056.
93. McCormick, A.D., McKillop, D., Butters, C.J. et al. ZD4522 - An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems. [Abstract]. J Clin Pharmacol 2000, 40: 1055.
94. Warwick, M.J., Dane, A.L., Raza, A. et al. Single and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 [Abstract]. Atherosclerosis 2000, 15: 39.
95. Martin, P.D., Dane, A.L., Nwose, D., Schneck, D.W., Warwick, M.J. Effects of age and gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor. Clin Pharmacol Ther 2001, 69: 56.
96. Simonson, S.G., Martin, P.D., Mitchell, P.D. et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in hepatically impaired subjects [Abstract]. Clin Pharmacol Ther 2001, 69: 86.
97. Tood, P.A., Goa, K.L. Simvastatin: A review of its pharmacological properties and therapeutic potential in hypercholesteroaemia. Drugs 1990, 40: 583-607.
98. Mauro, V.F. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993, 24: 195-202.
99. Cheng, H., Schwartz, M.S., Vickers, S. et al. Metabolic disposition of simvastatin in patients with T-tube drainage. Drug Metab Dispos 1994, 22: 139-42.
100. Vickers, S., Duncan, C.A., Vyas, K.P. et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990, 18: 476-83.
101. Vickers, S., Duncan, C.A., Chen I.-Wu., Rosegay, A., Duggan D.E. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990, 18: 138-45.
102. Prueksaritanont, T., Gorham, L.M., Ma, B. et al. In vitro metabolism of simvastatin in humans [sbt]identification of metabolizing enzyme sand effect of the drug on hepatic P450S. Drug Metab Dispos 1997, 25: 1191-9.
103. Transon, C., Leemann, T., Dayer, P. In vitro comparative inhibition profiles of major drug metabolizing cytochrome P-450 enzymes (CYP2C9, CYP2D and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996, 50: 209-15.
104. Bottorff, M., Hansten, P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors. The role of metabolism. Monograph for physicians. Arch Intern Med 2000, 160: 2273-80.
105. Prueksaritanont, T., Vega, J.M., Rogers, J.D. et al. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. J Clin Pharmacol 2000, 40: 1274-9.